[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369204-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369204-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","car-t-therapy-for-endocrine-neoplasms-novel-targets-and-combination-of-therapies","CAR-T therapy for endocrine neoplasms - novel targets and combination of therapies","","Endocrine malignancies form a heterogeneous tumor group with varied biology, including indolent and aggressive subtypes; metastatic disease signals high recurrence risk and weaker responses to conventional treatment. CAR-T cell immunotherapy represents a major advance for endocrine cancers, yet clinical efficacy remains limited. A key early step is identifying specific, safe targets. This mini review summarizes recent progress in target discovery and surveys combinatorial strategies to improve CAR T performance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/car-t-therapy-for-endocrine-neoplasms-novel-targets-and-combination-of-therapies/369204/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/car-t-therapy-for-endocrine-neoplasms-novel-targets-and-combination-of-therapies/369204.png","ImageObject",300,407,{"name":42,"@type":43},"Liam","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is metastatic endocrine cancer linked to poorer outcomes with conventional therapies?","Question",{"text":63,"@type":64},"Metastatic disease indicates a high probability of recurrence and reduced response to conventional treatments, reflecting the aggressive biology within endocrine malignancies.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is the main purpose of identifying targets before starting CAR-T development?",{"text":68,"@type":64},"Identifying specific and safe targets for endocrine cancer is described as the initial stage toward establishing an effective CAR-T treatment.",{"name":70,"@type":61,"acceptedAnswer":71},"How do combinatorial approaches aim to improve CAR-T effectiveness?",{"text":72,"@type":64},"The document highlights that various investigated therapies may enhance CAR T cell efficacy through different mechanisms, and it provides an overview of recent combinatorial approaches.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369204,1790241892,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","TYPE Mini Review  \nPUBLISHED 11 February 2025 DOI 10.3389/fendo.2025.1517525  \nOPEN ACCESS  \nEDITED BY  \nClaire Perks,  \nUniversity of Bristol, United Kingdom  \nREVIEWED BY  \nLan Jiang,  \nFirst Afﬁliated Hospital of Wannan Medical College, China  \n*CORRESPONDENCE  \nXingchen Liu  \n [liuxch14@lzu.edu.cn](liuxch14@lzu.edu.cn)[ ](liuxch14@lzu.edu.cn)Jun Cai  \n [cj13937612766@163.com](cj13937612766@163.com)[ ](cj13937612766@163.com)Chun Zhang  \n [260316@njucm.edu.cn](260316@njucm.edu.cn)[ ](260316@njucm.edu.cn)Rui Tu  \n [2454648880@qq.com](2454648880@qq.com)  \n†These authors have contributed equally to this work and share ﬁrst authorship  \nRECEIVED 26 October 2024  \nACCEPTED 23 January 2025  \nPUBLISHED 11 February 2025  \nCITATION  \nWang F, Zhang R, Zhou Z, Shi R, Peng F, Xu Y, Yang S, Wang Z, Zhang P, Tu R, Zhang C, Liu X and Cai J (2025) CAR-T therapy for endocrine neoplasms: novel targets and combination of therapies.  \nFront. Endocrinol. 16:1517525 .  \ndoi: 10.3389/fendo.2025.1517525  \nCOPYRIGHT  \n© 2025 Wang, Zhang, Zhou, Shi, Peng, Xu, Yang, Wang, Zhang, Tu, Zhang, Liu and Cai.  \nThis is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nCAR-T therapy for endocrine neoplasms: novel targets and combination of therapies  \nFang Wang 1†, Ruiqi Zhang 2†, Zhaokai Zhou 2†, Run Shi 3, Fu Peng 4, Yudi Xu 5, Shuai Yang 2, Zhan Wang 2, Pengpeng Zhang 6, Rui Tu 7*, Chun Zhang 8*, Xingchen Liu 9* and Jun Cai 9*  \n1 Department of Otolaryngology-Head and Neck Surgery, Xinyang Central Hospital, Xinyang, Henan, China, 2 Department of Urology, First Afﬁliated Hospital of Zhengzhou University, Henan Joint International Pediatric Urodynamic Laboratory, Zhengzhou, China, 3 Department of Oncology, The First Afﬁliated Hospital of Nanjing Medical University, Nanjing, China, 4 Department of Pharmacology, Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, China,  \n5 Department of Neurology, The First Afﬁliated Hospital of Zhengzhou University, Zhengzhou, Henan, China, 6 Department of Lung Cancer, Tianjin Lung Cancer Center, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China, 7 Department of Ultrasound, Xinyang Central Hospital, Xinyang, Henan, China, 8 Department of Gastroenterology, Afﬁliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China,  \n9 Department of Gynaecology, Xinyang Central Hospital, Xinyang, Henan, China  \nEndocrine malignancies constitute a heterogeneous tumour group with diverse biological characteristics. While typically indolent, they encompass aggressive types and presence of any metastatic sign indicates a high probability of recurrence and a diminished response to conventional therapies. Chimeric antigen receptor (CAR)-T cell immunotherapy has constituted a revolutionary advance in cancer treatment and exhibited signiﬁcant potential for application in endocrine cancer. However, limited effectiveness was displayed in clinical application, which necessitates the exploration of novel modalities . Identiﬁcation of speciﬁc and safe targets for endocrine cancer is the initial stage towards establishing a successful CAR-T treatment. Various therapies under investigation offer potential enhancements to CAR T cell efﬁcacy through diverse mechanisms. Herein, we ","cbCailtJ1FwYgK4R","https://ap.wps.com/l/cbCailtJ1FwYgK4R","pdf",812288,"English","# Introduction\n## CAR-T therapy rationale and challenges\n## Target identification for endocrine cancers\n## Combinatorial approaches to enhance CAR T efficacy","[{\"question\":\"Why is metastatic endocrine cancer linked to poorer outcomes with conventional therapies?\",\"answer\":\"Metastatic disease indicates a high probability of recurrence and reduced response to conventional treatments, reflecting the aggressive biology within endocrine malignancies.\"},{\"question\":\"What is the main purpose of identifying targets before starting CAR-T development?\",\"answer\":\"Identifying specific and safe targets for endocrine cancer is described as the initial stage toward establishing an effective CAR-T treatment.\"},{\"question\":\"How do combinatorial approaches aim to improve CAR-T effectiveness?\",\"answer\":\"The document highlights that various investigated therapies may enhance CAR T cell efficacy through different mechanisms, and it provides an overview of recent combinatorial approaches.\"}]","CAR-T therapy for endocrine neoplasms - novel targets and combination of therapies | PDF",1790181377,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc4801e48947f29789023c8759cb4b38.webp",983,1389,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6056f413c2368d87235cc71df3b22c10.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/30c84ec39e6ee2e95c2d96eeaa7afa0d.webp",981,1386,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b939b6debd0c21b8aefe0b565d949de1.webp",980,1385]